ProCE Banner Activity

TRIO COHORT: Real-World LA CAB for PrEP Over the First 2 Years

Conference Coverage
Slideset

In a retrospective electronic health record analysis, over the first 2 years of using long-acting cabotegravir for PrEP, the TRIO cohort resulted in high persistence and adherence rates, no HIV seroconversion, and few safety issues. However, there was inconsistency with CDC testing guidelines.

Released: October 25, 2024

Expiration: October 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare